
Please try another search
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson’s syndrome, and toxic epidermal necrolysis. The company also provides contract development and manufacturing organization services to biotech companies. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Gottingen for the development and commercialization of COVID-19 nanosized antibody. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Name | Age | Since | Title |
---|---|---|---|
Amir Reichman | 48 | 2021 | CEO & Director |
Mark S. Germain | 73 | 2018 | Chairman of the Board |
Avner Rotman | 82 | 2005 | Independent Director |
Adi Raviv | 69 | 2020 | Independent Director |
Morris C. Laster | 60 | 2017 | Independent Director |
Jay Green | 52 | 2021 | Independent Director |
Samuel J. Moed | 62 | 2020 | Director |
Matthias Dobbelstein | - | 2022 | Member of Scientific Advisory Board |
George H. Lowell | 80 | 2008 | Member of Scientific Advisory Board |
Yael Margolin | 71 | 2020 | Independent Director |
Jonathan Sadeh | - | 2024 | Member of Scientific Advisory Board |
Michael Schon | - | 2024 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review